FOLH1 and prostate carcinoma: In the present study, the small molecule PSMA ligand NG001 [23], labelled with 212Pb, was studied in PC-3 PIP and C4-2 prostate cancer models in vitro and in vivo to better understand how cellular PSMA expression, binding, and internalization influence biodistribution and the therapeutic efficacy of the radioligand.